There are sparse data on neoadjuvant systemic chemotherapy (NACT) in eyelid sebaceous gland carcinoma (SGC). The aim of this study was to evaluate efficacy and outcomes with NACT in eyelid SGC. We retrospectively analyzed 8 patients who received platinum-based NACT. The median number of cycles per patient was 4 (range, 3–5). The mean percentage reduction of tumor diameter after NACT was 71% (range, 30–100%). Two patients had a radiological complete response (CR). After NACT, surgical treatment for residual tumor was performed in 5 cases. One patient had a pathological CR and is recurrence free for 11 years. After a mean follow-up period of 44.5 months (range, 9–109), tumor recurrence occurred in 4 cases. Among these 4 cases, 3 were rechallenged with the same regimen and all responded. Systemic NACT has a role in eyelid SGC, downstages the tumor, and allows less aggressive and organ-sparing surgeries, warranting a prospective study.
Ocul Oncol Pathol

中文翻译：

---

眼睑皮脂腺癌的新辅助全身化疗：回顾性研究

关于眼睑皮脂腺癌 (SGC) 的新辅助全身化疗 (NACT) 的数据很少。本研究的目的是评估 NACT 在眼睑 SGC 中的疗效和结果。我们回顾性分析了 8 名接受铂类 NACT 的患者。每名患者的中位周期数为 4（范围，3-5）。NACT 后肿瘤直径的平均减少百分比为 71%（范围，30-100%）。两名患者有放射学完全缓解（CR）。NACT后对5例残留肿瘤进行手术治疗。一名患者有病理性 CR，并且 11 年无复发。平均随访 44.5 个月（范围 9-109）后，4 例肿瘤复发。在这 4 例中，有 3 例再次使用相同的治疗方案并全部缓解。全身性 NACT 在眼睑 SGC 中发挥作用，降低肿瘤的分期，
眼肿瘤病理